Many investigators have examined the moderating effects of DSM-IV Axis II personality disorders and psychopathological dimensional personality traits on treatment outcome in MDD. This literature was summarized in a narrative review 10 and in 2 more recent metaanalytic investigations, which focused exclusively on personality disorders. 12 , 13 Mulder 10 concluded that the strongest support for personality disorders as a predictor of treatment outcome for depressed patients comes from "the methodologically weakest studies." p 368 Indeed, most studies cited were statistically underpowered, and (or) did not employ random assignment or other methods of treatment control. This conclusion was supported in the metaanalysis conducted by Kool et al, 12 which included only well-designed RCTs; these investigators found no significant effects of personality disorders on treatment outcome. Although results from a more recent metaanalytic investigation led Newton-Howes et al 13 to challenge Kool et al, Newton-Howes et al's use of less stringent study inclusion criteria seems only to support Mulder's conclusion that significant effects emerge from methodologically weaker research designs.
Although the review of Mulder 10 included selected dimensional personality traits from the Eysenck Personality Questionnaire 14 and its precursor, the Maudsley Personality Inventory 15 and the TCI 16 and its precursor, the Tridimensional Personality Questionnaire, 17 investigations that used the NEO PI 18 and the later developed NEO PI-R 11 were not included. Presumably Mulder did not review the studies using these instruments, which were designed to assess the FFM, because the traits that compose this model were derived from nonclinical populations using mostly nonpsychopathological thematic sources, considered by many to measure only normal personality trait dimensions. 19 The NEO inventories include scales that assess accepted personality psychopathological traits (for example, neuroticism and [low] extraversion) that are identical or similar to other instruments and personality traits assessed by them. More importantly, is that the NEO inventories include domains from the FFM not assessed directly by these other instruments that are seemingly good predictors of treatment response. For example, the conscientiousness trait may be related to tighter adherence to treatment protocol; and the agreeableness domain, which contains aspects of interpersonal relatedness, trust, and compliance, may increase therapeutic alliance.
Investigators examining whether the personality traits of the FFM predict treatment response in patients with MDD have reported mixed results. Bagby et al 20 found that higher scores on extraversion predicted a positive outcome to various antidepressant medications, even after controlling for depression severity; Du et al 21 found that higher scores on the agreeableness domain predicted response to fluoxetine; whereas Peterson et al 22 reported that none of the domain scores from the FFM predicted treatment response in depressed subjects treated with fluoxetine.
Comparatively, fewer investigations have been conducted examining the role of personality in differential response to different types of empirically supported interventions for MDD. Numerous investigations examining potential treatment-specific moderating effects of clinical characteristics, including personality, on treatments for depression have used data from the TDCRP. 23 The TDCRP is a multisite study comparing the effectiveness of 3 forms of treatment for depression and a placebo condition-CBT, IPT, PHT plus clinical management, and a placebo plus clinical management. In the first of these investigations, Sotsky et al 24 reported that better social functioning and general well-being predicted positive treatment outcome among those treated with IPT. Those with reduced depressogenic cognitions, as measured by the DAS, 25 responded more positively to CBT and PHT plus clinical management than those in the placebo condition. In a subsequent analysis, Blatt et al 26, 27 examined the effects of 2 personality constructs-perfectionism and need for approval-also measured by the DAS, and reported that perfectionism predicted poorer treatment response across all treatment modalities, suggesting no treatmentspecific moderating effects for these personality characteristics.
In a naturalistic treatment outcome study, Rector et al 28 32 In a RCT depression trial in which participants were randomized to receive either CBT or IPT, investigators reported that the presence of high levels of avoidant and schizoid personality disorder symptoms, as measured by SCID-II, 33 were associated with poorer outcome to IPT, compared with CBT. These authors also found that higher scores on the personality trait of harm avoidance, measured with the TCI, 16 were associated with a poorer outcome in IPT but not CBT.
The goal of the current investigation was to continue this line of research examining the interaction between personality and treatment type in the prediction of differential treatment response using 2 well known and effective treatments for MDD-CBT and PHT-using a comprehensive taxonomy of universal personality traits that is currently the most predominant and frequently used dimensional model of personality-the FFM. 11 Despite its widespread use, to date no study has examined personality and its treatment-specific moderating effects using the FFM. A common shortcoming in studies examining personality and treatment outcome is the lack of statistical power. 10 We combined data from 2 RCTs, which included CBT and PHT treatment cells. The combined sample size (n = 275) generated enough power to detect at least moderate effect sizes, considered the minimal effect to be clinically meaningful.
34

Method
Subjects
The sample comprised 105 men and 175 women (mean age 41.9 years, SD 11.90), who participated in one of 2 randomized trials (Trial A/Trial B) at the CAMH. Both trials had the approval of the Research Ethics Board at the CAMH. A proportion (16.7%) of the data from Trial A is used in a previous manuscript. ; and willing to be randomized. Exclusion criteria were: presence or history of bipolar disorder, psychotic disorders, or substance use disorders; presence of borderline or antisocial personality disorder, as assessed by the SCID-II; current treatment with antidepressant medication or previous treatment with electroconvulsive therapy; or concurrent active medical illness.
Subjects were solicited through advertisements in local media. In Trial A, 307 were assessed following a telephone screen. Among these, 131 were excluded because they did not meet inclusion criteria; an additional 4 met the criteria but chose not to participate. Among the remaining 171, 56 were randomized to CBT, 57 to IPT, and 59 to PHT. Of these, 36 completed CBT, 38 IPT, and 32 PHT. As Trial B did not include an IPT condition, we did not include this treatment arm. In Trial B, 301 were assessed following an initial telephone screen. Among these, 141 were excluded because they did not meet inclusion criteria. Among the remaining 160, 90 were randomized to CBT and 70 to PHT; 69 completed CBT and 37 completed PHT.
Measures
Hamilton Depression Rating Scale
The HDRS is a semi-structured, clinician-rated interview designed to assess severity of depression; currently, it is the most widely used measure of depression severity in clinical trials.
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Revised NEO Personality Inventory The NEO PI-R is a self-report questionnaire designed to assess the FFM. 11 This instrument yields scale scores for 5
higher-order personality domains-neuroticism, extraversion, openness-to-experience, agreeableness, and conscientiousness-as well as the 30 lower-order facet traits (6 per each domain) ( Table 1) .
These domains, and the facet traits that compose them, were shown to be heritable, 38 biologically-based, 39 and generalizable across languages, cultures, and countries. 40, 41 Investigators have shown that domain and facet traits can be validly and reliably assessed in psychiatric patients, even in the context of acute symptom change.
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Procedure and Treatment Protocols
Callers interested in either trial telephoned intake workers, who provided more information about the study. If continued interest was expressed, a screening interview for study eligibility was performed over the telephone and those meeting study criteria were invited for a face-to-face interview.
Research assistants trained in diagnostic interviewing performed the assessment at CAMH. Those eligible were offered the opportunity to participate and if they agreed to randomization were asked to provide written informed consent and then assigned to one of the treatment conditions. 
Treatment Group Differences
There were no significant differences between the patients receiving CBT, compared with PHT, for age, t = 1.18, P = 0.12, or distribution of men and women, c 2 = 0.73, df 1, P = 0.39, nor were there any differences between the treatment groups for the personality domain traits, with, in all cases t < 1.90, mean value for P = 0.53, or personality facet traits, t < 1.68, mean value for P = 0.47. 
Personality and Treatment Outcome
Hierarchical linear regressions were conducted for each of the 5 NEO PI-R domain traits and 30 facet traits. The criterion variable was posttreatment HDRS score. In Step 1, pretreatment HDRS scores were entered to control for pretreatment depression severity. In Step 2, treatment condition was entered as a main effect; as there were no differences in outcome between treatment conditions, this variable was not interpreted and was only used to create the treatment condition by personality interaction. In
Step 3, one of the 5 domain traits or one of the 30 facet traits was entered as a main effect for personality. In Step 4, the treatment condition by personality interaction was entered. A significant main effect of personality indicates that personality predicts outcome regardless of treatment type; a significant interaction effect indicates that personality predicts differential response to treatment type. As the facets within a domain are correlated, a facet was considered a meaningful and unique moderator only if it remained significant after controlling for the common variance associated with the other remaining facets in that domain. To this end, the first unrotated factor of a common factor analysis of the remaining 5 facets, which represents the variance common to those facets, was entered into the regression as both a main effect and an interaction. Facets were considered unique predictors only if they contributed significantly following the inclusion of this measure of common facet variance.
Personality Domain Traits as Predictors of Treatment Outcome
Main Effects. There was only one significant main effect for openness, b = -0.26, t = 3.61, P < 001, R 2 = 0.11. Higher scores on openness at the beginning of treatment were associated with lower depression severity at treatment completion.
Interaction Effects. There was only one significant interaction effect for neuroticism, b = 0.90, t = 2.12, P < 0.04, R 2 = 0.07. Higher scores at pretreatment were associated with lower posttreatment depression severity for those receiving PHT, compared with those receiving CBT (Figure 1 ).
To evaluate the clinical significance of this interaction effect, we assessed the proportion of remission rates attendant on high or low status (SD 1) on this personality trait. Patients with high scores were more likely classified as remitters if 
Personality Facet Traits as Predictors of Treatment Outcome
Main Effects. There were 6 significant main effects for the personality facet traits: 2 from the extraversion domain-excitement seeking (b = -0.17, t = 2.29, P < 0.02, self-consciousness did not remain significant after controlling for the remaining 5 neuroticism facets, indicating that it is the variance common to all of the neuroticism facets that is associated with this moderation effect.
For the facets from the agreeableness domain, trust (DR 2 = 0.04, F 1,167 = 6.46, P = 0.01), straightforwardness (DR 2 = 0.02, F 1,167 = 4.18, P = 0.04), and tendermindedness (DR 2 = 0.04, F 1,167 = 7.20, P < 0.01), all remained significant after controlling for the remaining 5 agreeableness facets. Lower trust and straightforwardness scores were associated with lower depression severity following treatment with PHT, compared with those treated with CBT. Higher tendermindedness scores were associated with lower depression severity in the PHT condition, compared with those treated with CBT. Patients categorized as low scorers on trust were more likely to respond if treated with PHT, compared with CBT (86%, compared with 56%). Similarly, patients categorized as low scorers on straightforwardness were more likely to respond if treated with PHT, compared with CBT (100%, compared with 62%). Finally, patients categorized as high scorers on tendermindedness were more likely to respond if treated with PHT, compared with CBT (80%, compared with 54%).
Discussion
In the current study, depressed patients with higher scores on neuroticism are more likely to respond to PHT, compared with CBT. As neuroticism reflects the heritable predisposition to experience high levels of negative affect, one explanation for this result is that those with higher scores on this trait may be too emotionally dysregulated to recruit the psychological resources needed to enable cognitive strategies required for CBT. PHT may directly target neural systems involved in dysregulated emotions, circumventing the cognitive requirements for response to CBT. This interpretation is bolstered by outcomes from earlier studies indicating antidepressants, 43 especially SSRIs, 48 decrease levels of negative affect. One possible treatment implication of this finding is the potential benefit of treatment sequencing, 49 such that patients with high levels of neuroticism might prove to be best treated initially with pharmacotherapy, and then receive a trial of CBT, when they are able to fully use CBT strategies. As CBT has been demonstrated to confer a slight advantage over antidepressant medication in the prevention of depression recurrence, 50 this sequencing strategy maximizes the benefits of the superior effects of SSRIs in the treatment of the acute episode, and the protective effects of CBT for recurrence.
Patients scoring lower on the trust facet, a lower-order trait of the agreeableness domain, which assesses interpersonal aspects of personality, were more likely to respond to PHT, compared with CBT. Low scorers on the trust personality trait facet are described as cynical or skeptical and tend to see others as dishonest; these characteristics may impede the formation of a therapeutic alliance, which is the cornerstone of psychotherapy, 51 including CBT. 52 Although the capacity and disposition to trust is important in any physician-patient relationship, the results from the current study suggest it plays a less critical role in medication management. The straightforwardness facet, also of the agreeableness domain, reflects tendency toward sincerity, with high scorers on this trait described as frank and ingenuous. Low scorers may have a higher response rate to PHT as they benefit most from treatments that do not require disclosure of feelings. Curiously, high scorers on the tendermindedness facet trait had better outcome when treated with PHT, compared with CBT. High scorers on this trait are described as sympathetic and soft-hearted, whereas low scorers are described as obstinate and logical. Of the 4 significant interaction effects, this outcome is not readily understandable and may simply reflect a spurious effect.
Although the primary goal of the current investigation was to examine personality and treatment-specific moderating effects, several personality traits emerged as moderators of general treatment outcome. Facets from both the extraversion and openness-to-experience domain demonstrated significant predictive capacity; however, openness-to-experience was the only significantly predicting domain trait and 4 of 6 facets from this domain predicted treatment outcome after removing unique variance associated with the other facets, suggesting both general and unique predictive components associated with this personality trait. This result is particularly interesting as this personality domain is unique to the FFM in relation to the dimensional models of personality psychopathology and has been dismissed by most as unrelated to psychopathology. [53] [54] [55] Openness reflects "the recurrent need to enlarge and examine experience"-curiosity and imagination and flexibility in considering novel ideas, behaviours, and feelings. 56, p 167 This set of traits would seem to describe a characteristic predictive of response to psychotherapy; however, it may also reflect a general receptivity to treatment in general. To our knowledge, this is the first study to examine the effects of openness in the prediction of treatment outcome to both psychotherapy and PHT and the finding here certainly requires replication and further exploration.
Conclusion
The results from the current investigation suggest that treatment response for those with MDD may be optimized if patient personality traits are taken into consideration. One limitation of the current investigation is that our data analytic approach was designed to minimize type II error. We believe the significant results obtained are not attributable to chance, as they are logical and consistent with the broader literature on treatment outcome in MDD. We used stringent statistical tests and criteria to examine the unique and specific components of the significantly predicting personality traits, which minimize spurious and redundant effects.
One potential limitation of this investigation is that we relied on a single dimensional model-the FFM-using a self-report method of assessment. As the FFM readily captures the most important aspects of other dimensional models of personality 57 and even DSM-IV Axis II personality disorders, 58 we believe the results were highly generalizable.
Recent studies have also demonstrated that the self-report measure of the FFM used in this study (NEO PI-R, Form S) is highly correlated with third-person informant ratings 59 and with structured interviews of the FFM, 60,61 even for depressed patients in the acute phase of their depressive illness. 62 The results of the current investigation are only generalizable to one type of psychotherapy (CBT) and the antidepressant medications used in this study. As CBT and IPT have produced their own personality by treatment-specific moderating effect in comparison with one another, 30,32 the outcome may be different with IPT in comparison with PHT. The lack of statistical power prohibited us from examining that effect in this study. Similarly, one can only extrapolate findings from the current study to the antidepressant medications used, predominantly SSRIs. For example, as the short variant of the serotonin transporter polymorphism, which is thought to decrease transporter expression and serotonin reuptake, 63 and has been linked to neuroticism, 64 the effect of PHT on high neuroticism in the current study may not hold for other classes of antidepressant medication that have no direct action on the serotonin transporter, such as the noradrenergic and dopaminergic reuptake blockers and reversible monoamine oxidase inhibitors. Investigators conducting research in this area in the future might use other forms of empirically-supported psychotherapies and other classes of antidepressant medication. Finally, another potential limitation is that our exclusion criteria may limit the degree to which our results can be generalized to more pathological patients, especially those with high rates of comorbidity with other mental disorders. 
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